Royalty Pharma Retained Earnings (Accumulated Deficit) 2019-2024 | RPRX
Royalty Pharma retained earnings (accumulated deficit) for the quarter ending December 31, 2024 were $2.846B, a 13.03% increase year-over-year.
- Royalty Pharma retained earnings (accumulated deficit) for 2024 were $2.846B, a 13.03% increase from 2023.
- Royalty Pharma retained earnings (accumulated deficit) for 2023 were $2.518B, a 28.14% increase from 2022.
- Royalty Pharma retained earnings (accumulated deficit) for 2022 were $1.965B, a 12.88% decline from 2021.